Role of Serum Levels of Angiogenic Cytokines in Assessment of Angiogenesis after Stem Cell Therapy of Diabetic Patients with Critical Limb Ischemia

Cell Transplantation

Article

Libuse Pagacova¹  Martin Varga²  Libor Kolesar³  Vladimira Fejfarova⁴  Robert Bem⁴  Alexandra Jirkovska⁴  Michal Dubsky⁵  Edward. B. Jude⁶  Eva Sykova⁷ 

[1] Autotransfusion Unit, Institute for Clinical and Experimental Medicine, Prague, Czech Republic;Clinic of Transplant Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic;Department of Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czech Republic;Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic;Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic;First Medical Faculty, Charles University, Prague, Czech Republic;Diabetes Centre, Tameside Hospital NHS Foundation Trust and University of Manchester, Ashton-Under-Lyne, Lancashire, UK;Institute of Experimental Medicine, Czech Academy of Science, Prague, Czech Republic;

关键词: Systemic vasculogenesis;    Stem cell (SC) therapy;    Angiogenic cytokines;    Critical limb ischemia (CLI);   

DOI  :  10.3727/096368913X674071

 received in 2013-04-24, accepted in 2013-10-03,  发布年份 2014

来源: Sage Journals

【 摘 要 】

The release of proangiogenic cytokines into the circulation after stem cell (SC) therapy and compensatory increase of angiogenesis inhibitors may reflect local vasculogenesis but also can increase the risk of side effects. The aim of our study was to evaluate serum levels of angiogenic cytokines with regard to the assessment of local and systemic vasculogenesis in diabetic patients with no-option critical limb ischemia (NO-CLI). Twenty-five diabetic patients with NO-CLI treated with SCs isolated from bone marrow or stimulated peripheral blood were included in the study. Serum levels of proangiogenic cytokines (VEGF, bFGF, Ang-1, PDGF-AA, and PDGF-BB) and an antiangiogenic cytokine (endostatin) were assessed 6 months after cell treatment, compared to baseline values, and correlated with the number of injected CD34+ cells. The clinical effect of SC therapy (assessed by changes in TcPO2) and potential systemic vasculogenesis (assessed by eye fundus examination) were evaluated after 6 months. Serum levels of angiogenic inhibitor endostatin increased significantly after 1 and 3 months (p = 0.0003), but no significant increase in serum levels of proangiogenic cytokines was observed. A significant correlation between number of injected CD34+ cells and serum levels of endostatin was observed (r = 0.41, p < 0.05); however, proangiogenic cytokines did not correlate with CD34+ cells. No correlation between increase in TcPO2 after treatment and serum levels of any of the angiogenic cytokines were seen, and no signs of systemic vasculogenesis in the retina were observed after 6 months. Despite the significant increase in the levels of the angiogenic inhibitor endostatin following SC treatment, there was no risk of systemic vasculogenesis after SC therapy as documented by serum levels of proangiogenic cytokines or changes in the retina.

【 授权许可】

Unknown   
© 2014 Cognizant Comm. Corp.

【 图 表 】

Figure 5.

Figure 1.

Figure 1.

Figure 1.